Transitioning Alzheimer Disease Blood Biomarkers into Primary Care: Are We There Yet?
作者信息
Cousins Katheryn A Q, Shaw Leslie M
机构信息
Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, United States.
出版信息
Clin Chem. 2025 Apr 3;71(4):435-437. doi: 10.1093/clinchem/hvae211.
Abstract
摘要
相似文献
1
Transitioning Alzheimer Disease Blood Biomarkers into Primary Care: Are We There Yet?将阿尔茨海默病血液生物标志物应用于初级保健：我们做到了吗？
Clin Chem. 2025 Apr 3;71(4):435-437. doi: 10.1093/clinchem/hvae211.
2
Challenges in the practical implementation of blood biomarkers for Alzheimer's disease.阿尔茨海默病血液生物标志物实际应用中的挑战。
Lancet Healthy Longev. 2024 Oct;5(10):100630. doi: 10.1016/j.lanhl.2024.07.013. Epub 2024 Oct 3.
3
Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease.从脑脊液检测向血液检测转变，以促进阿尔茨海默病的诊断和疾病监测。
J Intern Med. 2021 Sep;290(3):583-601. doi: 10.1111/joim.13332. Epub 2021 Jun 26.
4
[Blood Based Biomarker for Optimization of Early and Differential Diagnosis of Alzheimer's Dementia].[用于优化阿尔茨海默病痴呆早期及鉴别诊断的血液生物标志物]
Fortschr Neurol Psychiatr. 2022 Jul;90(7-08):326-335. doi: 10.1055/a-1839-6237. Epub 2022 Jul 20.
5
Biomarkers for Alzheimer disease in cerebrospinal fluid, urine, and blood.脑脊液、尿液和血液中阿尔茨海默病的生物标志物。
Mol Diagn Ther. 2008;12(5):307-20. doi: 10.1007/BF03256296.
6
Menopausal vasomotor symptoms and plasma Alzheimer disease biomarkers.更年期血管舒缩症状与血浆阿尔茨海默病生物标志物
Am J Obstet Gynecol. 2024 Mar;230(3):342.e1-342.e8. doi: 10.1016/j.ajog.2023.11.002. Epub 2023 Nov 7.
7
Alzheimer Disease Biomarkers in Clinical Practice: A Blood-Based Diagnostic Revolution.阿尔茨海默病生物标志物在临床实践中的应用：基于血液的诊断革命。
J Prim Care Community Health. 2022 Jan-Dec;13:21501319221141178. doi: 10.1177/21501319221141178.
8
Accelerated longitudinal changes and ordering of Alzheimer disease biomarkers across the adult lifespan.阿尔茨海默病生物标志物在成年期的加速纵向变化和排序。
Brain. 2022 Dec 19;145(12):4459-4473. doi: 10.1093/brain/awac238.
9
Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care.用于在初级保健和二级保健中检测阿尔茨海默病的血液生物标志物。
JAMA. 2024 Oct 15;332(15):1245-1257. doi: 10.1001/jama.2024.13855.
10
Advances in blood biomarkers for Alzheimer disease (AD): A review.阿尔茨海默病（AD）血液生物标志物的研究进展：综述。
Kaohsiung J Med Sci. 2024 Aug;40(8):692-698. doi: 10.1002/kjm2.12870. Epub 2024 Jun 18.
引用本文的文献
1
Electronic health records to test multimorbidity influences to plasma biomarker interpretation for Alzheimer's disease.电子健康记录用于测试多种疾病对阿尔茨海默病血浆生物标志物解读的影响。
medRxiv. 2025 Aug 19:2025.08.16.25333799. doi: 10.1101/2025.08.16.25333799.
2
Comparison of plasma p-tau217/Aβ42, p-tau217, and Aβ42/Aβ40 biomarkers by race to detect Alzheimer's disease.通过种族比较血浆p-tau217/Aβ42、p-tau217和Aβ42/Aβ40生物标志物以检测阿尔茨海默病。
Alzheimers Dement. 2025 Aug;21(8):e70469. doi: 10.1002/alz.70469.
本文引用的文献
1
Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care.用于在初级保健和二级保健中检测阿尔茨海默病的血液生物标志物。
JAMA. 2024 Oct 15;332(15):1245-1257. doi: 10.1001/jama.2024.13855.
2
Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease.可接受的淀粉样蛋白病理血生物标志物检测性能——来自全球阿尔茨海默病首席执行官倡议的建议。
Nat Rev Neurol. 2024 Jul;20(7):426-439. doi: 10.1038/s41582-024-00977-5. Epub 2024 Jun 12.
3
Alzheimer disease blood biomarkers: considerations for population-level use.阿尔茨海默病血液生物标志物：在人群水平应用的考虑因素。
Nat Rev Neurol. 2024 Aug;20(8):495-504. doi: 10.1038/s41582-024-00989-1. Epub 2024 Jun 11.
4
Blood tests for Alzheimer's disease: The impact of disease prevalence on test performance.阿尔茨海默病的血液检测：疾病患病率对检测性能的影响。
Alzheimers Dement. 2024 May;20(5):3661-3663. doi: 10.1002/alz.13762. Epub 2024 Mar 6.
5
Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays.在记忆诊所中进行的血浆和脑脊液生物标志物检测：磷酸化tau 免疫分析的头对头比较。
Alzheimers Dement. 2023 May;19(5):1913-1924. doi: 10.1002/alz.12841. Epub 2022 Nov 12.
Zotero 插件